Literature DB >> 4019959

Overview of corticosteroid therapy.

S C Siegel.   

Abstract

Corticosteroids have been recognized as useful in the management of asthma for the past 35 years. Controversy remains as to their precise indications, dosage, and optimal methods of administration. Only recently has objective evidence been presented confirming their usefulness in acute severe attacks and status asthmaticus. In the treatment of the latter, high doses of methylprednisolone (125 mg every 6 hours) has been shown to be more effective than lower doses. The corticosteroids are also useful diagnostically to determine reversibility of airway obstruction in the bronchitis-emphysema syndrome. To prevent adrenal insufficiency, they are mandatory for patients previously receiving long-term systemic corticosteroid therapy who are undergoing stress (e.g., surgery). Indications for chronic severe asthma are the least well established. Patients with severe incapacitating asthma uncontrolled by bronchodilators or cromolyn should be considered candidates for corticosteroid therapy. When long-term therapy is necessary, aerosolized corticosteroids or alternate-day therapy are preferable to daily dosing. Regardless of the route used, it is advisable to limit the use of these agents to patients who clearly require them and to take all precautions to minimize side effects. Neither method, especially when higher doses are used, obviates possible development of serious complications.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4019959     DOI: 10.1016/0091-6749(85)90647-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

Review 1.  Drug therapy approaches in the treatment of acute severe asthma in hospitalised children.

Authors:  L K DeNicola; M O Gayle; K V Blake
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

2.  Anti-inflammatory effects of glucocorticoids and cyclosporin A on human basophils.

Authors:  G Marone; C Stellato; A Renda; A Genovese
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 3.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 4.  Drug treatment of allergic conjunctivitis. A review of the evidence.

Authors:  G Ciprandi; S Buscaglia; P M Cerqueti; G W Canonica
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 5.  Pharmacokinetic optimisation of asthma treatment.

Authors:  A M Taburet; B Schmit
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

6.  Cyclosporin A increases the pulmonary eosinophilia induced by inhaled Aspergillus antigen in mice.

Authors:  J M Wang; M Denis; M Fournier; M Laviolette
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.